Neqlofol (Beclometasone Dipropionate, Formoterol Fumarate Dihydrate)

Beclometasone dipropionate binds to glucocorticoid receptors in airway cells, modulating gene transcription to suppress inflammatory mediators such as cytokines, chemokines, and adhesion molecules. This anti‑inflammatory action reduces airway swelling, mucus production, and hyper‑responsiveness, contributing to improved breathing in chronic respiratory conditions.

The dose of Neqlofol is individualized and set by the prescribing clinician based on the severity of the disease, patient age, and response to therapy. Patients should follow the specific instructions on the prescription label and consult their healthcare provider for any adjustments.

Safety data for Neqlofol in pregnancy and lactation are limited. The decision to use it should be made by a qualified healthcare professional after weighing potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment options with their doctor.

To order Neqlofol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Neqlofol combines beclometasone, an inhaled corticosteroid, with formoterol, a long‑acting β2‑agonist, similar to other ICS/LABA products such as budesonide/formoterol. The clinical efficacy is comparable, offering both anti‑inflammatory and bronchodilator effects. Choice among products often depends on device preference, dosing schedule, patient tolerance, and formulary considerations.

Neqlofol should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the inhaler away from direct sunlight and do not expose it to freezing temperatures. Follow any additional handling instructions provided in the product insert.

Neqlofol is delivered via inhalation using a metered‑dose inhaler or similar device. Patients should prime the inhaler according to the manufacturer’s guidelines, exhale fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the device. A spacer may be recommended for certain patients to improve drug deposition.

Serious risks include paradoxical bronchospasm, which presents as sudden worsening of breathing, and adrenal suppression, which can affect the body’s stress response with prolonged use. Additionally, severe allergic reactions such as anaphylaxis may occur. Patients should seek immediate medical attention if they experience these or any unexpected symptoms.

Neqlofol is contraindicated in individuals with known hypersensitivity to beclometasone, formoterol, or any excipients in the formulation. It should also be avoided in patients who have experienced a severe paradoxical bronchospasm with inhaled corticosteroids or long‑acting β2‑agonists. Clinicians must assess each patient’s medical history before prescribing.